CAI
Caris Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.71
+0.49%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +18.0%
- EBITDA
- +23.9%
- EPS
- -17.2%
Three-year CAGR
- Revenue
- +46.5%
- EBITDA
- +106.2%
- EBIT
- +117.5%
- Net income
- -90.8%
- EPS
- +29.3%
- Free cash flow
- +126.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026